Nifty
Sensex
:
:
9314.95
31605.22
285.90 (3.17%)
995.92 (3.25%)

Pharmaceuticals & Drugs - API

Rating :
63/99  (View)

BSE: 540222 | NSE: LAURUSLABS

449.65
-6.90 (-1.51%)
27-May-2020 | 3:54PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  457.00
  •  459.40
  •  446.75
  •  456.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  438224
  •  1970.47
  •  536.00
  •  295.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,815.43
  • 19.09
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,848.34
  • 0.33%
  • 2.75

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.04%
  • 6.83%
  • 15.13%
  • FII
  • DII
  • Others
  • 11.29%
  • 30.22%
  • 4.49%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.56
  • 6.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.78
  • -2.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.60
  • -21.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 30.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.13

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 13.18

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
839
635
32%
730
529
38%
712
588
21%
551
539
2%
Expenses
647
523
24%
581
442
32%
575
513
12%
467
458
2%
EBITDA
192
112
71%
148
88
69%
138
76
82%
83
81
3%
EBIDTM
23%
18%
20%
17%
19%
13%
15%
15%
Other Income
2
2
4%
2
1
35%
1
11
-87%
4
3
74%
Interest
21
18
18%
21
24
-12%
26
25
4%
23
22
1%
Depreciation
46
43
6%
48
43
11%
48
40
20%
46
38
20%
PBT
127
53
141%
82
23
259%
66
22
202%
19
23
-14%
Tax
17
9
77%
8
5
66%
9
6
65%
4
6
-29%
PAT
110
43
155%
73
18
312%
57
16
249%
15
17
-9%
PATM
13%
7%
10%
3%
8%
3%
3%
3%
EPS
10.30
4.06
154%
6.87
1.67
311%
5.29
1.52
248%
1.42
1.56
-9%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
2,832
2,292
2,056
1,905
1,778
1,327
1,160
Net Sales Growth
24%
11%
8%
7%
34%
14%
 
Cost Of Goods Sold
1,413
1,225
1,056
989
1,000
821
720
Gross Profit
1,418
1,067
1,000
915
777
505
439
GP Margin
50%
47%
49%
48%
44%
38%
38%
Total Expenditure
2,271
1,936
1,643
1,497
1,415
1,131
956
Power & Fuel Cost
-
109
94
66
58
50
35
% Of Sales
-
5%
5%
3%
3%
4%
3%
Employee Cost
-
276
238
205
175
131
103
% Of Sales
-
12%
12%
11%
10%
10%
9%
Manufacturing Exp.
-
179
151
139
107
81
48
% Of Sales
-
8%
7%
7%
6%
6%
4%
General & Admin Exp.
-
97
73
65
49
28
27
% Of Sales
-
4%
4%
3%
3%
2%
2%
Selling & Distn. Exp.
-
32
24
23
16
12
13
% Of Sales
-
1%
1%
1%
1%
1%
1%
Miscellaneous Exp.
-
17
6
9
9
7
10
% Of Sales
-
1%
0%
0%
1%
1%
1%
EBITDA
561
356
413
408
362
195
204
EBITDA Margin
20%
16%
20%
21%
20%
15%
18%
Other Income
9
16
29
33
4
34
9
Interest
90
88
80
100
111
101
59
Depreciation
187
164
125
106
86
62
33
PBT
294
120
237
235
169
67
121
Tax
38
26
70
44
35
-2
24
Tax Rate
13%
22%
29%
19%
21%
-2%
20%
PAT
255
94
168
191
134
68
97
PAT before Minority Interest
255
94
168
191
134
68
97
Minority Interest
0
0
0
0
0
0
0
PAT Margin
9%
4%
8%
10%
8%
5%
8%
PAT Growth
172%
-44%
-12%
43%
97%
-30%
 
EPS
23.88
8.83
15.83
20.78
21.37
44.27
63.56

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,558
1,483
1,330
857
722
358
Share Capital
106
106
106
82
82
78
Total Reserves
1,447
1,371
1,219
771
637
277
Non-Current Liabilities
295
174
132
428
364
204
Secured Loans
259
142
125
354
304
188
Unsecured Loans
0
0
0
106
0
0
Long Term Provisions
30
21
15
7
5
4
Current Liabilities
1,424
1,307
1,121
884
802
711
Trade Payables
488
312
263
248
231
227
Other Current Liabilities
244
231
199
141
133
164
Short Term Borrowings
684
759
644
481
432
312
Short Term Provisions
7
5
14
14
7
7
Total Liabilities
3,278
2,964
2,584
2,169
1,888
1,273
Net Block
1,629
1,481
1,230
1,021
801
499
Gross Block
2,105
1,794
1,419
1,106
986
623
Accumulated Depreciation
476
313
189
85
185
124
Non Current Assets
1,815
1,716
1,444
1,166
1,024
697
Capital Work in Progress
110
163
143
70
110
116
Non Current Investment
3
3
3
7
7
0
Long Term Loans & Adv.
26
29
26
29
94
68
Other Non Current Assets
47
40
41
39
12
13
Current Assets
1,463
1,248
1,140
1,003
862
575
Current Investments
0
0
0
0
0
0
Inventories
682
585
509
487
476
328
Sundry Debtors
710
571
568
445
285
195
Cash & Bank
3
3
4
29
59
23
Other Current Assets
68
31
34
18
43
29
Short Term Loans & Adv.
35
59
25
24
23
20
Net Current Assets
39
-59
19
119
60
-136
Total Assets
3,278
2,964
2,584
2,169
1,888
1,273

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
298
342
332
182
-65
121
PBT
120
237
235
169
67
121
Adjustment
255
216
199
201
136
83
Changes in Working Capital
-52
-49
-52
-154
-251
-59
Cash after chg. in Working capital
323
404
382
215
-48
145
Interest Paid
0
0
0
0
0
0
Tax Paid
-25
-62
-50
-33
-17
-23
Other Direct Exp. Paid
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
Cash From Investing Activity
-253
-384
-289
-312
-397
-312
Net Fixed Assets
-255
-394
-354
-77
-354
Net Investments
-7
-1
-24
-7
-19
Others
9
12
90
-228
-24
Cash from Financing Activity
-45
42
-54
103
486
203
Net Cash Inflow / Outflow
0
1
-10
-27
24
12
Opening Cash & Equivalents
3
2
13
40
15
3
Closing Cash & Equivalent
3
3
2
13
40
15

Financial Ratios

Standalone /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
146
139
125
499
420
189
ROA
3%
6%
8%
7%
4%
8%
ROE
6%
12%
18%
19%
14%
33%
ROCE
8%
14%
17%
16%
14%
20%
Fixed Asset Turnover
1.18
1.29
1.53
1.73
1.66
1.87
Receivable days
102
100
96
74
65
61
Inventory Days
101
96
94
97
110
103
Payable days
73
61
59
59
69
87
Cash Conversion Cycle
130
136
131
112
106
77
Total Debt/Equity
0.67
0.66
0.64
1.20
1.14
1.54
Interest Cover
2
4
3
3
2
3

News Update


  • Laurus Labs gets USFDA’s nod for ANDAs TLE 400, TLE 600 tablets
    19th May 2020, 12:04 PM

    These approvals enables Laurus Labs to launch both the products in several LMIC markets

    Read More
  • Laurus Labs donates Hydroxychloroquine tablets, Rs 50 lakh to fight covid-19 in Telangana
    27th Mar 2020, 15:22 PM

    The company has donated 1 lakh tablets to beat COVID 19 virulent disease

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.